|
New Products
- Caplacizumab (Cablivi) is a humanised bivalent nanobody that consists of two identical humanised building blocks (PMP12A2hum1), genetically linked by a three-alanine linker, targeting the A1-domain of von Willebrand Factor and inhibiting the interaction between von Willebrand Factor and platelets. It prevents the ultralarge von Willebrand Factor-mediated platelet adhesion, and also affects the disposition of von Willebrand Factor, leading to transient reductions of total von Willebrand Factor antigen levels and to concomitant reduction of factor VIII:C levels during treatment. Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura, in conjunction with plasma exchange and immunosuppression. Cablivi powder for injection contains caplacizumab 10 mg and is available in a pack size of 1 or 7 vials with prefilled syringe(s) containing water for injection as solvent.
- Melatonin (Slenyto) is a naturally occurring hormone produced by the pineal gland and is structurally related to serotonin. Melatonin is associated with the control of circadian rhythms and entrainment to the light-dark cycle. It is also associated with a hypnotic effect and increased propensity for sleep. The activity of melatonin at the MT1 and MT2 receptors is believed to contribute to its sleep-promoting properties via their distinct actions on the circadian clock. The MT1 receptors are thought to inhibit neuronal firing, while the MT2 receptors have been implicated in the phase-shifting response. Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder and/or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. Slenyto tablets contain melatonin 1 mg (available in packs of 60) or 5 mg (available in packs of 30).
|
|
|
New Indications
- Dapagliflozin (propanediol monohydrate) (Forxiga) is now indicated in adults for the treatment of symptomatic heart failure with reduced ejection fraction, as an adjunct to standard of care therapy.
- Ustekinumab (Stelara) is now indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents aged 6 years and older who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
|
|
|
New Contraindications
- Cefotaxime sodium (DBL Cefotaxime Sodium for Injection) is now contraindicated with pregnancy and during lactation.
- Citalopram HBr (Cipramil) should not be used in combination with monoamine oxidase inhibitors (MAOIs), including selegiline in daily doses exceeding 10 mg/day.
- Metoclopramide HCl/paracetamol (Anagraine) is now contraindicated in children under 18 years of age.
- Vincristine sulfate (DBL Vincristine Sulfate Injection) is now contraindicated with intrathecal administration.
- Zoledronic acid (DBL Zoledronic Acid) is now contraindicated in patients with severe renal impairment (ClCr ≤ 30 mL/min).
|
|
|
This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.
|
|
|
|
|
|
|
|
|
